A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies-Reference-Cited by-同舟云学术

A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapies

Published:2023-01 Issue:1 Volume:25 Page:1-13
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Dashnau Jennifer L.^ORCID,Xue Qiong,Nelson Monica^ORCID,Law Eric^ORCID,Cao Lan,Hei Derek^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference99 articles.

1. Advances in pluripotent stem cells: History, mechanisms, technologies, and applications;Liu;Stem Cell Rev Rep,2020

2. Engineering the next generation of cell-based therapeutics;Bashor;Nat Rev Drug Discov,2022

3. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients;Deuse;Nat Biotechnol,2019

4. Generation of hypoimmunogenic human pluripotent stem cells;Han;Proc Natl Acad Sci U S A,2019

5. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors;Takahashi;Cell,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerating Diverse Cell-Based Therapies Through Scalable Design;Annual Review of Chemical and Biomolecular Engineering;2024-07-24

2. Generation of hypoimmunogenic universal iPSCs through HLA-type gene knockout;2024-07-03

3. Cultivated meat: research opportunities to advance cell line development;Trends in Cell Biology;2024-07

4. Clearance of residual genome editing components used for ex vivo genome-editing of allogeneic cell therapy products;Cytotherapy;2024-07

5. Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee;Cytotherapy;2024-06